Premium
Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile‐onset diabetes mellitus
Author(s) -
Danowski T. S.,
Cohn R. E.,
Limaye N. R.,
Novak J. F.,
Saul R.,
Sunder J. H.,
Moses C.
Publication year - 1965
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196566716
Subject(s) - medicine , endocrinology , urine , diabetes mellitus , thyroid function , blood sugar , chemistry , uric acid , ketone bodies , renal function , blood lipids , cholesterol , thyroid , metabolism
Ethyl‐α (p‐chlorophenoxy)isobutyrate (Atromid‐S or CPIB) was administered for three months to 18 patients with diabetes mellitus of juvenile onset. The intensity of the diabetes, ;udging by serial fasting blood sugar levels, glucose tolerance tests, 24 hour urine glucose excretion, and tests of fractional urine specimens for sugar and acetone did not change significantly. The drug did not produce a hypolipidemic effect but pretherapy values for serum lipoprotein cholesterol and triglycerides were almost always within the normal range. Several nonsustained increases in cephalin flocculation and one instance of prothrombin time prolongation were observed. Other hepatic function indices remained unchanged. A slight increase in serum total CO 2 , and a slight decrease in serum inorganic phosphorus were not statistically significant. Serum uric acid did decrease: the differences between pretherapy and therapy values were statistically significant. No other parameters of blood, serum, body fluids, hepatic, thyroid, adrenal, or pituitary function were discernibly affected.